AT702

AT702

Status

Pre-Clinical

Therapeutic Approach

Restoring or Replacing Dystrophin

Duchenne can be caused by a number of genetic mutations (changes). AT702 is an investigational exon skipping gene therapy candidate for patients with a duplication of exon 2 in the DMD gene with the goal of a producing a full-length or near full-length dystrophin protein.

Status

On April 5, 2020, Audentes Therapeutics shared an update with the community regarding their Duchenne program and COVID-19.

Sponsor

This program is sponsored by Astellas Gene Therapies.

Media

JUNE 2021

Astellas Gene Therapies at the PPMD 2021 Virtual Annual Conference


Pre-recorded content for PPMD's 2021 Virtual Annual Conference On-Demand Library

Join Our Mailing List